BRPI0915813A2 - estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos - Google Patents

estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos

Info

Publication number
BRPI0915813A2
BRPI0915813A2 BRPI0915813-8A BRPI0915813A BRPI0915813A2 BR PI0915813 A2 BRPI0915813 A2 BR PI0915813A2 BR PI0915813 A BRPI0915813 A BR PI0915813A BR PI0915813 A2 BRPI0915813 A2 BR PI0915813A2
Authority
BR
Brazil
Prior art keywords
vaccine composition
stabilizer
live attenuated
vaccine
attenuated flaviviruses
Prior art date
Application number
BRPI0915813-8A
Other languages
English (en)
Inventor
Francon Alain
Brass Olivier
Chouvenc Pierre
Leleu Amandine
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of BRPI0915813A2 publication Critical patent/BRPI0915813A2/pt
Publication of BRPI0915813B1 publication Critical patent/BRPI0915813B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

estabilizante para composições de vacina, composição de vacina aquosa em massa estabilizada, método de estabilização de um ou mais flavivírus atenuados vivos, composição de vacina seca, método para a preparação de uma vacina e kit de vacina flaviviral a presente invenção refere-se a um estabilizante para composições de vacina compreendendo um ou mais flavivírus atenuados vivos, a uma composição de vacina em massa estabilizada com este estabilizante, particularmente uma composição de vacina seca preparada a partir desta composição da vacina em massa, e a um método para a estabilização de um ou mais flavivírus atenuados vivos.
BRPI0915813-8A 2008-07-09 2009-07-09 Estabilizante para composições de vacina, composição de vacina aquosa em massa estabilizada, método de estabilização de um ou mais flavivírus atenuados vivos, composição de vacina seca, métodos para a preparação de vacinas e kit de vacina flaviviral BRPI0915813B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08305390A EP2143440A1 (fr) 2008-07-09 2008-07-09 Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP08305390.0 2008-07-09
PCT/EP2009/004980 WO2010003670A1 (en) 2008-07-09 2009-07-09 Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses

Publications (2)

Publication Number Publication Date
BRPI0915813A2 true BRPI0915813A2 (pt) 2019-04-09
BRPI0915813B1 BRPI0915813B1 (pt) 2022-02-08

Family

ID=39942863

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915813-8A BRPI0915813B1 (pt) 2008-07-09 2009-07-09 Estabilizante para composições de vacina, composição de vacina aquosa em massa estabilizada, método de estabilização de um ou mais flavivírus atenuados vivos, composição de vacina seca, métodos para a preparação de vacinas e kit de vacina flaviviral

Country Status (17)

Country Link
US (2) US8142795B2 (pt)
EP (3) EP2143440A1 (pt)
JP (1) JP5586598B2 (pt)
KR (1) KR101679723B1 (pt)
CN (1) CN102089002B (pt)
AR (1) AR072796A1 (pt)
AU (1) AU2009267401B2 (pt)
BR (1) BRPI0915813B1 (pt)
CA (1) CA2729758C (pt)
DK (1) DK2310048T3 (pt)
ES (1) ES2429130T3 (pt)
IL (1) IL210289A0 (pt)
MX (1) MX2011000312A (pt)
MY (1) MY150613A (pt)
TW (1) TWI460190B (pt)
WO (1) WO2010003670A1 (pt)
ZA (1) ZA201100107B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
WO2011135393A1 (es) * 2010-04-27 2011-11-03 Universidad Manuela Beltran Vacuna biologica autologa contra el cancer
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
ES2626297T3 (es) 2011-08-12 2017-07-24 Merial, Inc. Preservación asistida por vacío de productos biológicos, en particular de vacunas
EP3246400B1 (en) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
WO2013172467A1 (ja) * 2012-05-14 2013-11-21 帝人株式会社 放射線滅菌耐性蛋白質組成物
WO2013177172A2 (en) * 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
EP3932422A1 (en) 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CN104812408A (zh) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
US10429129B2 (en) 2013-10-16 2019-10-01 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
NZ741421A (en) 2014-05-14 2023-05-26 Vitamfero S A Methods for freeze-drying and rehydrating biologics
EP3188751A1 (en) 2014-09-02 2017-07-12 Sanofi Pasteur Vaccine compositions against dengue virus diseases
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
CN106667944A (zh) * 2015-11-11 2017-05-17 北京泰德制药股份有限公司 含有前列腺素类药物的缓释制剂
TWI766876B (zh) * 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
JP7051132B2 (ja) * 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
CA3062549A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CN111065732A (zh) 2017-09-11 2020-04-24 Imba-莫利库尔生物技术研究所 肿瘤类器官模型
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
JP7261239B2 (ja) 2017-10-16 2023-04-19 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生組換えフラビウイルスなどから成る安定したワクチン組成物およびその調製方法
MX2020005857A (es) 2017-12-07 2020-09-09 Merck Sharp & Dohme Formulaciones de composiciones de vacuna contra el virus del dengue.
CN108938574B (zh) * 2018-08-14 2020-10-16 江苏省农业科学院 猪伪狂犬病活疫苗冻干耐热保护剂、其制备方法及用途
US20220193222A1 (en) * 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
KR102544928B1 (ko) * 2022-12-28 2023-06-20 주식회사 중앙백신연구소 아미노산을 유효성분으로 함유하는 동물용 백신 또는 진단용 항원의 안정성 증진용 조성물 및 이의 용도

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3162019A (en) 1962-11-16 1964-12-22 Bethlehem Steel Corp Method and apparatus for freezing liquids to be used in a freeze-drying process
GB1195363A (en) 1966-06-17 1970-06-17 Struthers Scientific Int Corp Freeze Drying
US3313032A (en) 1966-07-28 1967-04-11 George J Malecki Freeze-drying process and apparatus
US3655838A (en) 1969-03-20 1972-04-11 Organon Method of pelletizing analytical or immunological reagents
DE2659546A1 (de) 1976-12-30 1978-07-13 Boehringer Mannheim Gmbh Verfahren zur herstellung von gefrorenen granulaten
US4211015A (en) 1978-01-18 1980-07-08 Baxter Travenol Laboratories, Inc. Method and apparatus for making novel particulate compositions
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
GB8802142D0 (en) * 1988-02-01 1988-03-02 Air Prod & Chem Method of freezing liquid & pasty products & freezer for carrying out said method
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
US5307640A (en) 1993-01-25 1994-05-03 E. I. Du Pont De Nemours And Company Apparatus and method for producing frozen particles of a liquid
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
JP4504464B2 (ja) 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー キメラフラビウイルスワクチン
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1165128A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-2 virus vaccine
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
CA2941182A1 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
PT1159968E (pt) 2000-05-30 2008-11-20 Univ Mahidol Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina
JP2004517699A (ja) 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
DE10124902A1 (de) 2001-05-22 2002-11-28 Bayer Ag Partikuläre Feststoffe oberflächenaktiver Verbindungen
CA3060687C (en) 2001-05-22 2021-05-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
ES2439724T3 (es) 2001-06-01 2014-01-24 Sanofi Pasteur Biologics, Llc Vectores de flavivirus quiméricos
US7459160B2 (en) 2002-01-15 2008-12-02 Acambis Inc. Chimeric flaviviruses
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
WO2003102166A2 (en) 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
EP2591771A1 (en) * 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
US20030215455A1 (en) * 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
EP1575979B1 (en) 2002-11-15 2009-12-23 Sanofi Pasteur Biologics Co. West nile virus vaccine
WO2004052293A2 (en) * 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
US7836606B2 (en) 2004-07-23 2010-11-23 Bayer Technology Services Gmbh Sterile freezing, drying, storing, assaying and filling process
MX2007015873A (es) 2005-06-17 2008-04-22 Sanofi Pasteur Cepa atenuada de virus de dengue serotipo 1.
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CN101237888A (zh) * 2005-08-04 2008-08-06 惠氏公司 畜禽疫苗的稳定剂
JP5138601B2 (ja) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
EP2851087B1 (en) 2006-11-07 2017-04-19 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
KR102134980B1 (ko) * 2007-04-06 2020-07-16 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물

Also Published As

Publication number Publication date
DK2310048T3 (da) 2013-10-07
BRPI0915813B1 (pt) 2022-02-08
EP2310048B1 (en) 2013-09-11
CN102089002A (zh) 2011-06-08
CA2729758C (en) 2017-03-07
EP2687229A1 (en) 2014-01-22
EP2310048A1 (en) 2011-04-20
US8142795B2 (en) 2012-03-27
US20100015180A1 (en) 2010-01-21
US20130028934A1 (en) 2013-01-31
JP5586598B2 (ja) 2014-09-10
MX2011000312A (es) 2011-03-01
ES2429130T3 (es) 2013-11-13
WO2010003670A1 (en) 2010-01-14
CA2729758A1 (en) 2010-01-14
IL210289A0 (en) 2011-03-31
AU2009267401B2 (en) 2014-12-11
AU2009267401A1 (en) 2010-01-14
MY150613A (en) 2014-01-30
AR072796A1 (es) 2010-09-22
EP2143440A1 (fr) 2010-01-13
TW201014868A (en) 2010-04-16
ZA201100107B (en) 2012-03-28
CN102089002B (zh) 2014-12-10
KR20110053325A (ko) 2011-05-20
KR101679723B1 (ko) 2016-11-25
TWI460190B (zh) 2014-11-11
JP2011527300A (ja) 2011-10-27

Similar Documents

Publication Publication Date Title
BRPI0915813A2 (pt) estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos
ATE523207T1 (de) Stabilisatoren für gefriergetrocknete impfstoffe
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
BR112015011244A8 (pt) análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
BR112014012524A2 (pt) composições compreendendo um componente de estabilidade do prazo de validade
BRPI0909630B8 (pt) composição em suspensão aquosa particularmente adequada para injeção dentro do olho
BR112016003127A2 (pt) “composições e métodos para modular rna”
AR065467A1 (es) Composiciones de tabaco y metodos de preparacion
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112014015908A2 (pt) composição
BR112013003145A2 (pt) composição para controle de artrópodes nocivos e método para o controle de artrópodes nocivos
BR112015012972A2 (pt) método para tratar uma formação subterrânea, composição para tratamento de uma formação subterrânea, e, método para preparo de uma composição aquosa para tratamento de uma formação subterrânea
BRPI0823272A2 (pt) conceito com recheio e método
BR112014009376A2 (pt) composições
BRPI0918058A8 (pt) Uso de composições de composto fungicida para o controle de certos fungos da ferrugem
BR112015001728B8 (pt) composições de condicionador
BR112017022821A2 (pt) solução aquosa homogênea de quitosana injetável apresentando um ph próximo do ph fisiológico
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
BRPI0709361B8 (pt) composição, métodos para a preparação de um alimento e método para o tratamento de listeria
MX339361B (es) Derivados de alternano.
BR112013026602A2 (pt) processo para a produção de um recheio de torta de queijo, recheio de torta de queijo armazenável à temperatura ambiente, processo para a obtenção de uma torta de queijo, uso do recheio de torta de queijo e uso de ovos pasteurizados numa composição alimentar
BR112013005532A2 (pt) agente terapêutico para dor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.